

PROGRESS IN BIOCHEMICAL PHARMACOLOGY

Volume 12

**DRUGS AFFECTING THE
RENIN-ANGIOTENSIN-
ALDOSTERONE SYSTEM**

08 459

Drugs Affecting the Renin-Angiotensin-Aldosterone System

Use of Angiotensin Inhibitors

Volume Editors

G. S. STOKES, Sydney, and K. D. G. EDWARDS, New York, N.Y.

Kanematsu Memorial Institute, Sydney Hospital, Sydney and

Clinical Physiology and Renal Service, Memorial Sloan Kettering Cancer Center,
New York, N.Y.

98 figures and 18 tables, 1976



Progress in Biochemical Pharmacology

- Vol. 9: Drugs and the Kidney. Editor: EDWARDS, K. D. G. (Sydney). XII + 274 p.
64 fig., 43 tab., 1974
ISBN 3-8055-1693-2
- Vol. 10: Lipids and Tumors. Editor: CARROLL, K. K. (London, Ont.). X + 400 p., 32 fig.,
60 tab., 1974
ISBN 3-8055-1708-4
- Vol. 11: Biological Basis of Clinical Effect of Bleomycin. Editor: CAPUTO, A. (Rome). X +
230 p., 74 fig., 69 tab., 1976
ISBN 3-8055-2338-6

Cataloging in Publication

Kanematsu Conference on the Kidney, 5th, Sydney, 1975

Drugs affecting the renin-angiotensin-aldosterone system: use of angiotensin inhibitors; proceedings

Volume editors, G.S. Stokes and K.D.G. Edwards. Basel, New York, Karger, 1976.
(Progress in biochemical pharmacology, v. 12)

1. Hypertension - diagnosis - congresses 2. Renin - metabolism - congresses 3. Angiotensin - antagonists & inhibitors - congresses 4. Aldosterone - metabolism - congresses I. Stokes, G.S., ed. II. Edwards, K. David G., ed. III. Title IV. Series
W1 PR666H v. 12/WK180-K16-1975d

ISBN 3-8055-2410-2

All rights, including that of translation into other languages, reserved.

Photomechanic reproduction (photocopy, microcopy) of this book or parts thereof without special permission of the publishers is prohibited.

- © Copyright 1976 by S. Karger AG, Basel (Switzerland), Arnold-Böcklin-Strasse 25
Printed in Switzerland by Buchdruckerei National-Zeitung AG, Basel
ISBN 3-8055-2410-2

In STOKES and EDWARDS: *Drugs Affecting the Renin-Angiotensin-Aldosterone System. Use of Angiotensin Inhibitors*
Prog. biochem. Pharmacol., vol. 12, pp. XIII-XIV (Karger, Basel 1976)

Introduction

This volume contains a collection of recent work on the use of angiotensin inhibitors in the diagnosis of human hypertension, and in analysing the pathophysiology of certain experimental situations, such as sodium depletion, high output heart failure, acute renal failure or renal-clip hypertension.

Theoretically, the actions of angiotension could be inhibited by preventing its binding to receptors, by interfering at any stage in its production from renin substrate or by interfering with the production or actions of its target hormones, the most important of which is aldosterone. Numerous potential modes of inhibition exist. Interference with the production of renin substrate from the liver or of renin from the kidneys, competitive inhibition of renin or of the enzyme which converts the decapeptide angiotensin I to angiotensin II, and antagonists or antibodies to the effector angiotensins 'II' (the octapeptide) and 'III' (the heptapeptide) have all been described, as have inhibitors of aldosterone biosynthesis and action.

The book does not attempt to deal in a sequential way with the entire subject of inhibition of the renin-angiotensin system. Some topics which are adequately reviewed elsewhere, such as the blockade of renin release and the role of aldosterone antagonists, are not mentioned, while others, namely competitive inhibition of renin and inhibition of converting enzyme, are each the subject of a single special chapter. The principle thrust of this presentation is to explore the practical application of angiotensin analogues, which have proved the most specific type of angiotensin inhib-

itor yet devised for clinical use. The analogue which has had the widest use is the octapeptide saralasin ('P113' – Norwich Pharmacal Company) in which sarcosine has been substituted for aspartic acid at the N-terminal end of the angiotensin II molecule and alanine for phenylalanine at the C-terminal end. The abbreviated chemical nomenclature we have used for this peptide is Sar¹-Ala⁸-angiotensin II. Other analogues discussed are Sar¹-Ile⁸-angiotensin II and Sar¹-Thr⁸-angiotensin II.

The contributing authors, all of whom have been prominent in recent developments in this field, were originally invited to present their papers at the Fifth Kanematsu Conference on the Kidney. This conference, which was held at Sydney Hospital in February 1976 as a satellite of the Fourth Meeting of the International Society of Hypertension, had as its topic *The Use of Angiotensin Inhibitors in Clinical Diagnosis*. The introductory reviews in section I were contributed by Prof. J. O. DAVIS, who delivered the 1975 Volhard Lecture of the International Society of Hypertension on the subject of blocking agents and the renin-angiotensin system, and by Prof. EDGAR HABER, whose studies with the nonapeptide converting enzyme inhibitor in normal subjects have paved the way for understanding the role of the renin-angiotensin system in the adjustments to posture and sodium depletion in man. Both these authors graciously submitted manuscripts even though they were unable to come to Australia for the Conference. Sections II and III, covering experimental and clinical research, respectively, contain the 16 papers which were read at the Conference, together with the transcripts of the discussion periods which followed each pair of papers.

In the task of organising the Fifth Kanematsu Conference and editing the papers and transcripts, we have had unstinting support and much practical help from the members of the Cardio-Renal Unit, Sydney Hospital. We owe a particular debt of gratitude to Mr. IAN THORNELL, Dr. HELEN OATES and Miss JUDY GAIN.

G. S. STOKES
K. D. G. EDWARDS

Contents

<i>Introduction</i>	XIII
---------------------------	------

Section I: General Reviews

Angiotensin II Blockade and the Functions of the Renin-Angiotensin System

J. O. DAVIS, R. H. FREEMAN, B. E. WATKINS, G. A. STEPHENS and G. M. WILLIAMS, Columbia, Mo.

1

Introduction	1
Effects of an Angiotensin II Antagonist on Aldosterone Secretion in the Dog.....	2
Effect of Angiotensin II Blockade on Aldosterone Secretion in the Rat	5
Angiotensin II Blockade in Experimental High Output Failure and in Experimental Renovascular Hypertension	9
Summary	14
References	14

Experimental and Clinical Studies with Converting Enzyme Inhibitor

E. HABER and A. C. BARGER, Boston, Mass.

16

Introduction	16
Renin and Sodium Balance	17
Studies in Normal Human Subjects	20
Experimental Renovascular Hypertension	22
Renin-Dependent Hypertension in Human Subjects	26
Conclusion	29
References	29

Section II: Studies in Experimental Animals

Comparative Studies of the Humoral and Arterial Pressure Responses to Sar¹-Ala⁸-, Sar¹-Ile⁸- and Sar¹-Thr⁸-Angiotensin II in the Trained, Unanaesthetized Dog

E. L. BRAVO, M. C. KHOSLA and F. M. BUMPUS, Cleveland, Ohio 33

Introduction	33
Methods	34
Results	35
Effect on Arterial Blood Pressure	35
Effect on PRA	38
Effect on Plasma Aldosterone	38
Discussion	38
Summary	39
References	39

Stimulating Effects of Angiotensin I, Angiotensin II and des-Asp¹-Angiotensin II on Steroid Production in vitro and its Inhibition by Sar¹-Ala⁸-Angiotensin II

R. HEPP, C. GRILLET, A. PEYTREMANN and M. B. VALLOTTON, Geneva 41

Introduction	41
Methods	42
Results	42
Discussion	45
Summary	46
References	47

Discussion 49

Effect of Adrenal Arterial Infusion of Saralasin (P113) on Aldosterone Secretion

J. R. BLAIR-WEST, J. P. COGHLAN, D. A. DENTON, H. D. NIALL, B. A. SCOGGINS and G. W. TREGGAR, Parkville, Vict. 53

Introduction	53
Results and Discussion	54
Conclusions	61
Summary	61
References	61

Effects of Saralasin on Renal Function in the Rat

K. G. HOFBAUER, K. BAUREISS, H. ZSCHIEDRICH and F. GROSS, Heidelberg 63

Introduction	63
Materials and Methods	64
Isolated Perfused Rat Kidney	64
Acute Renal Failure	65
Substances	65
Statistical Analysis	65
Experiments	66
Isolated Perfused Rat Kidney	66
Acute Renal Failure	67
Results	68
Isolated Perfused Rat Kidney	68
Acute Renal Failure	70
Discussion	71
Intrinsic Activity of AII Antagonists	71
Renal Haemodynamics and Circulating AII	72
Intrarenal Formation of AII	73
Autoregulation and Intrarenal AII	74
Renin Release	74
Renal Prostaglandins	75
Acute Renal Failure	75
Summary	76
Acknowledgements	77
References	77

<i>Discussion</i>	84
-------------------------	----

Effects of Angiotensin Antagonists in Various Forms of Experimental Arterial Hypertension

C. M. FERRARIO, F. M. BUMPUS, Z. MASAKI, M. C. KHOSLA and J. W. McCUBBIN, Cleveland, Ohio 86

Introduction	86
Methods	87
Results	88
Effect of Angiotensin Antagonists on Renovascular Hypertension	88
Findings in Chronic Hypertension Due to Cellophane Perinephritis	90
Effect of Angiotensin Blockers in Malignant Hypertension	91
Discussion	92
Summary	95
Acknowledgements	95
References	96

Antagonists, Inhibitors and Antisera in the Evaluation of Vascular Renin Activity

The Role of Local Generation of Angiotensin II

J. D. SWALES, Leicester 98

Introduction	98
Vascular Wall Renin Activity	99
Changes in Vascular Renin	99
Role of Vascular Renin Activity	100
Vascular Renin and Angiotensin Antisera	101
Pressor Responsiveness to AII and Sodium Balance	104
AII Antagonist versus Antiserum	105
Timing of Pressor Changes after Nephrectomy	108
Response to AII Antagonist and Inhibitor after Nephrectomy	109
Conclusions	110
Summary	111
References	111

Discussion 114

The Use of Saralasin to Evaluate the Function of the Brain Renin-Angiotensin System

I. A. REID, San Francisco, Calif. 117

Introduction	117
Effects of Central Administration of Renin	119
Drinking	119
Blood Pressure	120
ADH Secretion	122
Effects of Central Administration of Substrate	124
Effects of Central Administration of Agents which Block the Renin-Angiotensin System	125
Drinking	126
Blood Pressure	127
Possible Role of Centrally Generated Angiotensin II in Hypertension	129
ADH Secretion	130
Concluding Remarks	130
Summary	131
References	132

Competitive Inhibitors of Renin

A Review

K. POULSEN, Copenhagen, J. BURTON and E. HABER, Boston, Mass. 135

Introduction	135
Results and Discussion	136

Summary	140
References	140
<i>Discussion</i>	142

Section III: Clinical Studies

Angiotensin II Blockade in Normal Man and Patients with Essential Hypertension. Blood Pressure Effects Depending on Renin and Sodium Balance

H. R. BRUNNER, Lausanne, H. GAVRAS, Boston, Mass., A. B. RIBEIRO and L. POSTERNAK, New York, N.Y. 145

Introduction	145
Methods	146
Normal Volunteers	146
Patients with Essential Hypertension	147
Laboratory Determinations	149
Results	149
Normotensive Volunteers	149
Blood Pressure	151
Sodium Balance	151
Plasma Renin Activity	151
Patients with Essential Hypertension	152
Blood Pressure	154
Sodium Balance	157
Plasma Renin Activity	157
Discussion	157
Summary	160
References	161

The Role of Renin in the Control of Blood Pressure in Normotensive Man

P. J. MULROW and R. NOTH, New Haven, Conn. 163

Introduction	163
Methods	163
Results	166
Normal Subjects	166
Cirrhotic Patients	167
Discussion	167
Summary	169

Contents	X
References	169
<i>Discussion</i>	170
<i>Changes of Blood Pressure, Plasma Renin Activity and Plasma Aldosterone Concentration following the Infusion of Sar¹-Ile⁸-Angiotensin II in Hypertensive, Fluid and Electrolyte Disorders</i>	
T. YAMAMOTO, K. DOI, T. OGIHARA, K. ICHIHARA, T. HATA and Y. KUMAHARA, Osaka	174
Introduction	174
Materials and Methods	176
Results	177
Normal Subjects in Three Different States of Sodium Balance	177
Patients with Hypertension, Fluid and Electrolyte Disorders	178
Relation between BP Changes and Pre-Infusion PRA	183
Relation between PAC Changes and Pre-Infusion PRA	183
Relationships between Changes in MBP, PRA and PAC	183
Discussion	183
Summary	186
References	187
<i>Angiotensin II Blockade in Hypertensive Dialysis Patients</i>	
G. A. MACGREGOR, London, and P. M. DAWES, Alderley Park, Cheshire	190
Introduction	190
Methods	191
Case Reports	192
Discussion	196
Summary	198
Acknowledgements	198
References	198
<i>Discussion</i>	200
<i>Angiotensin Antagonists as Diagnostic and Pharmacologic Tools</i>	
W. A. PETTINGER and H. C. MITCHELL, Dallas, Texas	203
Introduction	203
Pharmacokinetics of Saralasin	205
Diagnostic Use of Saralasin	206

Hypotensive Response.....	208
Augmentation of Split Vein Renins.....	209
Autonomous Aldosterone Secretion.....	210
Angiotensin Antagonists as Tools in Clinical Pharmacology.....	211
Summary.....	212
References.....	212

The Use of Saralasin in the Recognition of Angiotensinogenic Hypertension

D. H. P. STREETEN, T. G. DALAKOS and G. H. ANDERSON, jr., Syracuse, N.Y.. 214

Introduction.....	214
Method of Use of Saralasin.....	216
Need for Antecedent Na Loss.....	216
Method of Administration of Saralasin.....	218
Significance of Hypotensive Response to Saralasin.....	219
Nature of Renal and Renovascular Lesions in Saralasin Responders.....	222
Summary.....	224
Références.....	224

Discussion..... 227

The Effects of the Angiotensin II Antagonist Saralasin on Blood Pressure and Plasma Aldosterone in Man in Relation to the Prevaling Plasma Angiotensin II Concentration

J. J. BROWN, W. C. B. BROWN, R. FRASER, A. P. LEVER, J. J. MORTON, J. I. S. ROBERTSON, E. A. ROSEI and P. M. TRUST, Glasgow, U.K. 230

Introduction.....	230
Methods.....	231
Results.....	233
Normal Subjects.....	233
Essential Hypertension.....	234
Primary Aldosteronism.....	234
Hypertension with Severe Chronic Renal Failure.....	234
Hypertension with Unilateral Renal Artery Stenosis.....	236
Relationship between Basal Plasma Angiotensin II Concentration and Blood Pressure Change during Saralasin Infusion.....	236
Relationship between Basal Plasma Angiotensin II Concentration and Change in Plasma Aldosterone during Saralasin Infusion.....	237
Discussion.....	237
Summary.....	239
Acknowledgements.....	240
References.....	240

*Haemodynamic Effects of Sar¹-Ala⁸-Angiotensin II in Patients
with Renovascular Hypertension*

R. FAGARD, A. AMERY, P. LIJNEN, T. REYBROUCK and L. BILLIET, Leuven 242

Introduction	242
Methods.....	243
Results.....	244
Characteristics of the Patients	244
Mean Arterial Pressure and Heart Rate in Sodium-Replete Patients	244
Mean Arterial Pressure and Haemodynamic Variables in Sodium-Deplete Patients.....	245
Mean Arterial Pressure in Patients Studied before and after Sodium Depletion	246
Discussion	247
Summary	248
References	248

Discussion 250

Subject Index 252

Section I: General Reviews

In STOKES and EDWARDS: *Drugs Affecting the Renin-Angiotensin-Aldosterone System. Use of Angiotensin Inhibitors*
Prog. biochem. Pharmacol., vol. 12, pp. 1-15 (Karger, Basel 1976)

Angiotensin II Blockade and the Functions of the Renin-Angiotensin System

JAMES O. DAVIS, RONALD H. FREEMAN, BARRY E. WATKINS,
GREGORY A. STEPHENS and GARY M. WILLIAMS

Department of Physiology, University of Missouri School of Medicine,
Columbia, Mo.

Contents

Introduction	1
Effects of an Angiotensin II Antagonist on Aldosterone Secretion in the Dog	2
Effect of Angiotensin II Blockade on Aldosterone Secretion in the Rat	4
Angiotensin II Blockade in Experimental High Output Failure and in Experimental Renovascular Hypertension	9
Summary	14
References	14

Introduction

In 1960-62; a large body of evidence accumulated to show that the renin-angiotensin system is a primary controller of aldosterone secretion [1]. Most of the early evidence came from studies in dogs and man and attempts to extend these findings to other species, especially the rat, failed to show a clear-cut relationship. Also, many of the observations were made during sodium depletion, which is a potent stimulus for aldosterone secretion. BLAIR-WEST *et al.* [2] have done extensive studies on the mechanisms controlling aldosterone secretion during sodium depletion in sheep and reported that factors other than the renin-angiotensin system, ACTH and plasma electrolyte concentrations are involved. The present report includes extensive studies of the mechanisms controlling adrenal steroid secretion, during sodium depletion in the dog

and rat, and during thoracic caval constriction in the dog, by use of angiotensin II blockade. In addition, data are presented on the role of the renin-angiotensin system in experimental high output failure and in experimental renovascular hypertension.

Effects of an Angiotensin II Antagonist on Aldosterone Secretion in the Dog

The angiotensin II analogue which has been used most extensively and most successfully for angiotensin II blockade is 1-sarcosine-8-alanine angiotensin II. Since most of the controversy in the past has centered around the control mechanisms for aldosterone secretion during sodium depletion, our most extensive studies have been directed at this specific problem by use of Sar¹-Ala⁸-angiotensin II. However, even before blocking agents were available, the effects of bilateral nephrectomy were studied in sodium-depleted hypophysectomized dogs [3]. Aldosterone secretion fell to very low levels following nephrectomy and corticosterone production which was very low as a result of hypophysectomy fell further after nephrectomy (fig. 1). The experiments were conducted in hypophysectomized dogs to prevent a high level of ACTH secondary to laparotomy from obscuring a possible fall in aldosterone secretion after removal of the kidneys. When the problem of the control of aldosterone secretion during sodium depletion was reinvestigated recently by use of the angiotensin II antagonist, Sar¹-Ala⁸-angiotensin II [4], aldosterone secretion fell to levels indistinguishable from zero in 5 of 7 dogs (table I); in these studies, dexamethasone was given to depress ACTH release. Interesting incidental findings were the striking increase in plasma renin activity (PRA) and the decrease in arterial pressure. As suggested elsewhere [5], it seems likely that the increase in PRA resulted from interruption of the negative feedback of angiotensin II on the JG cells and from the fall in arterial pressure. The studies were conducted in anaesthetized dogs with a chronic indwelling catheter for collection of adrenal venous blood and for direct measurement of the rate of aldosterone secretion.

In recent unpublished observations, this experiment was repeated with measurements of the concentration of plasma aldosterone by radioimmunoassay in conscious sodium-depleted dogs. Sar¹-Ala⁸-angiotensin II was given for prolonged periods up to 210 min. A striking fall to the extent of 73–92% in the plasma aldosterone level occurred and




Fig. 1. Effects of bilateral nephrectomy in sodium-depleted hypophysectomized dogs. For comparison, data are presented for anesthetized, stressed, normal dogs. Reprinted with permission of the *Journal of Clinical Investigation* [3].

was sustained in 2 of the 3 dogs throughout the period of infusion of the angiotensin II antagonist. In the third animal, plasma aldosterone decreased initially and then increased from this very low level during the last hour of analogue infusion. Under these circumstances, the presence of an increased plasma level of angiotensin II might have produced a decrease in the efficacy of Sar¹-Ala⁸-angiotensin II in the maintenance of a low plasma level of aldosterone; an increase in PRA did occur in all 3 animals. The expected progressive fall in arterial pressure also occurred. Conscious normal dogs studied similarly failed to show a change in either PRA or in arterial pressure.

The observations during sodium-depletion were extended to another experimental model in the dog, namely chronic constriction of the thoracic inferior vena cava. The results in this model have important clinical

Table I. Effects of Sar¹-Ala⁸-angiotensin II on aldosterone secretion (ng/min) in sodium-depleted dogs

Dog No.	Control periods		Infusion of angiotensin antagonist			Recovery periods	
	0 min	15 min	15 min	30 min	45 min	45 min	60 min.
1	22	23	4	0	8	33	19
2	5	10	5	2	2	11	—
3	26	13	7	8	6	32	57
4	9	6	4	2	2	3	2
5	27	10	3	0	0	27	27
6	11	12	6	4	3	17	13
7	11	16	4	3	2	20	19
$\bar{x}$	15.9	12.9	4.7	2.7	3.3	21.3	22.8
SEM	3.4	3.1	0.5	1.0	1.0	4.3	7.6
p			<0.01	<0.01	<0.01		




Fig. 2. Effects of intravenous infusion of the angiotensin II antagonist, Sar¹-Ala⁸-angiotensin II on steroid secretion in dogs with chronic thoracic inferior vena caval constriction. The abbreviations C₁, C₂ are for control periods and R₁, R₂ are for recovery periods. The three experimental periods, E₁, E₂, and E₃, are for measurements made at 15, 30, and 45 min of infusion of the angiotensin II antagonist. Reprinted with permission of *Science* [4].